Current Topics in Microbiology and Immunology

Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

Editors: Rodriguez, Moses (Ed.)

  • The authors offer help to clinicians and hope to patients
  • Adopts a novel, multifaceted approach to basic science
see more benefits

Buy this book

eBook $219.00
price for USA (gross)
  • ISBN 978-3-540-73677-6
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $279.00
price for USA
  • ISBN 978-3-540-73676-9
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Softcover $279.00
price for USA
  • ISBN 978-3-642-43783-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

"There is a need for a paradigm shift in our thinking about the pathogenesis of multiple sclerosis."

Challenging Charcot’s hypothesis that inflammatory response is the primary contributor to demyelination, Dr. Rodriguez and colleagues take a fresh, bold look at the causes and possible treatments of MS.

Assuming oligodendrocyte injury as a prerequisite to MS, the authors explore viruses, toxins and genetic defects as possible culprits. They present novel methods to interrupt and reverse demyelination. This book examines the correlation between axonal loss and clinical deficits, including the implied role of the CD8+ T cell and perforin. It assesses proteases, specifically, kallikrein 6, which are strongly associated with active demyelination. By directing natural autoantibodies against oligodendrocytes that demonstrate remyelination in animal models, the authors envision clinical trials for remyelination enhancement.

As internationally recognized specialists in a wide range of MS disciplines, the authors explore genetic tools for identifying patients who are most likely to experience spontaneous remyelination. Epidemiology studies offer additional avenues of treatment. Examples include uric acid, statin drugs, estrogen and progesterone.

MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science—and their applications in understanding cause and treatment—the authors offer help to clinicians and hope to patients.

Table of contents (14 chapters)

  • Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications

    Pittock, S. J. (et al.)

    Pages 1-17

  • Pathological Heterogeneity of Idiopathic Central Nervous System Inflammatory Demyelinating Disorders

    Lucchinetti, C.

    Pages 19-43

  • Multiple Sclerosis Genetics

    McElroy, J. P. (et al.)

    Pages 45-72

  • Imaging of Remyelination and Neuronal Health

    Erickson, B. J.

    Pages 73-92

  • Immunological Aspects of Axon Injury in Multiple Sclerosis

    Howe, C. L.

    Pages 93-131

Buy this book

eBook $219.00
price for USA (gross)
  • ISBN 978-3-540-73677-6
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $279.00
price for USA
  • ISBN 978-3-540-73676-9
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Softcover $279.00
price for USA
  • ISBN 978-3-642-43783-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Advances in Multiple Sclerosis and Experimental Demyelinating Diseases
Editors
  • Moses Rodriguez
Series Title
Current Topics in Microbiology and Immunology
Series Volume
318
Copyright
2008
Publisher
Springer-Verlag Berlin Heidelberg
Copyright Holder
Springer-Verlag Berlin Heidelberg
eBook ISBN
978-3-540-73677-6
DOI
10.1007/978-3-540-73677-6
Hardcover ISBN
978-3-540-73676-9
Softcover ISBN
978-3-642-43783-0
Series ISSN
0070-217X
Edition Number
1
Number of Pages
XIV, 362
Topics